Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN)
1,467.00
+251.00 (20.64%)
Jun 4, 2026, 5:31 PM IDT
TLV:TKUN Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 9.1 | 34.95 | 44.23 | 49.3 | 37.03 | |
Revenue Growth (YoY) | -73.96% | -20.97% | -10.28% | 33.13% | 70.97% |
Cost of Revenue | 7.35 | 29.53 | 32.7 | 31.19 | 29.38 |
Gross Profit | 1.75 | 5.43 | 11.53 | 18.11 | 7.65 |
Selling, General & Admin | 10.47 | 12.62 | 22.82 | 23.95 | 27.66 |
Research & Development | - | 0.83 | 3.89 | 5.16 | 7.2 |
Other Operating Expenses | -1.62 | -0.12 | -0.81 | -0.33 | 0.85 |
Operating Expenses | 9.72 | 19.98 | 39.19 | 44.45 | 50.7 |
Operating Income | -7.97 | -14.55 | -27.66 | -26.34 | -43.05 |
Interest Expense | -1.12 | -1.88 | -2.3 | -1.77 | -1.28 |
Interest & Investment Income | 0.04 | - | 0.13 | 0.09 | 0.01 |
Earnings From Equity Investments | - | - | -0.38 | - | - |
EBT Excluding Unusual Items | -9.05 | -16.44 | -30.21 | -28.02 | -44.32 |
Impairment of Goodwill | -11.27 | -22.34 | -59.63 | -17.57 | - |
Gain (Loss) on Sale of Investments | - | -4.73 | -0.43 | 1.93 | - |
Gain (Loss) on Sale of Assets | -0.84 | - | -0.17 | - | - |
Asset Writedown | - | - | - | -15.27 | - |
Other Unusual Items | 5.34 | 3.4 | -3.56 | 9.79 | 10.29 |
Pretax Income | -15.82 | -40.1 | -93.99 | -49.14 | -34.03 |
Income Tax Expense | - | - | 0.03 | 0.01 | - |
Earnings From Continuing Operations | -15.82 | -40.1 | -94.02 | -49.15 | -34.03 |
Minority Interest in Earnings | -0.03 | 0 | 5.13 | 0.91 | 1.38 |
Net Income | -15.85 | -40.1 | -88.89 | -48.24 | -32.65 |
Net Income to Common | -15.85 | -40.1 | -88.89 | -48.24 | -32.65 |
Shares Outstanding (Basic) | 1 | 1 | 1 | 0 | 0 |
Shares Outstanding (Diluted) | 1 | 1 | 1 | 0 | 0 |
Shares Change (YoY) | 1.48% | 32.86% | 29.54% | 15.79% | 23.01% |
EPS (Basic) | -18.66 | -47.90 | -141.05 | -99.16 | -77.72 |
EPS (Diluted) | -18.66 | -47.90 | -141.05 | -99.16 | -77.72 |
Free Cash Flow | 2.01 | -3.78 | -4.12 | -23.2 | -33.49 |
Free Cash Flow Per Share | 2.37 | -4.52 | -6.54 | -47.70 | -79.70 |
Gross Margin | 19.25% | 15.52% | 26.06% | 36.73% | 20.66% |
Operating Margin | -87.53% | -41.63% | -62.53% | -53.44% | -116.25% |
Profit Margin | -174.17% | -114.73% | -200.97% | -97.85% | -88.17% |
Free Cash Flow Margin | 22.08% | -10.82% | -9.31% | -47.07% | -90.43% |
EBITDA | 3.96 | 14.22 | 29.08 | 9.2 | -25.89 |
EBITDA Margin | 43.52% | 40.69% | 65.74% | 18.66% | -69.92% |
D&A For EBITDA | 11.93 | 28.77 | 56.73 | 35.54 | 17.15 |
EBIT | -7.97 | -14.55 | -27.66 | -26.34 | -43.05 |
EBIT Margin | -87.53% | -41.63% | -62.53% | -53.44% | -116.25% |